Pilot study of pentoxifylline in hepatopulmonary syndrome
Rajasekhar Tanikella, George M. Philips, Dorothy K. Faulk, Steven M. Kawut, Michael B. Fallon – 30 July 2008 – Hepatopulmonary syndrome (HPS) results when chronic liver disease or portal hypertension causes intrapulmonary microvascular dilatation with hypoxemia. In experimental HPS, tumor necrosis factor alpha (TNF‐α) overproduction contributes to vasodilatation, which is improved by pentoxifylline, a TNF‐α inhibitor. The effectiveness of pentoxifylline in humans is unknown.